Co-Authors
This is a "connection" page, showing publications co-authored by Carlo Salvarani and Giovanni Dolci.
Connection Strength
1.909
-
High-dose glucocorticoids pulse-therapy for beta-coronaviridae pneumonia: a systematic literature review and case-series of Coronavirus disease-2019. Clin Exp Rheumatol. 2021 Sep-Oct; 39(5):1119-1125.
Score: 0.931
-
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients. Front Cell Dev Biol. 2020; 8:609204.
Score: 0.232
-
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 01 01; 181(1):24-31.
Score: 0.230
-
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia. Clin Exp Rheumatol. 2020 Nov-Dec; 38(6):1215-1222.
Score: 0.229
-
The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients. PLoS One. 2021; 16(5):e0251768.
Score: 0.059
-
Methylprednisolone as rescue therapy after tocilizumab failure in patients with severe COVID-19 pneumonia. Clin Exp Rheumatol. 2021 Sep-Oct; 39(5):1141.
Score: 0.058
-
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020 10 21; 18(1):405.
Score: 0.057
-
TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. Contemp Clin Trials. 2020 11; 98:106165.
Score: 0.057
-
Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e474-e484.
Score: 0.056